Among patients with RET-arranged lung cancer treated with cabozantinib, RET rearrangements may be actionable drivers, according to a study published in The Lancet Oncology.1
In a prospective phase 2 trial, researchers led by Alexander Drilon, MD, of the Memorial Sloan Kettering Cancer Center in New York, New York, evaluated 26 patients who had RET-rearranged lung adenocarcinoma treated with cabozantinib to assess for overall response and activity. Twenty-five patients were deemed assessable.
Partial responses were observed in 7 of the 25 patients, and the most common fusion type–KIF5B-RET–was found in 16 patients.
Grade 3 treatment-related adverse events among the 26 patients given cabozantinib included lipase elevation (15%), increased alanine aminotransferase (8%), increased aspartate aminotransferase (8%), decreased platelet count (8%), and hypophosphatemia (8%).
RELATED: Non-Small Cell Lung Cancer Treatment Regimens
“An improved understanding of tumor biology and novel therapeutic approaches will be needed to improve outcomes with RET-directed targeted treatment,” the authors conclude.
- Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016 Nov 4. doi: 10.1016/S1470-2045(16)30562-9 [Epub ahead of print]